At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 150 enrolled
Drug / intervention
Tranexamic acid +1 moredrug
Likely dose
Tranexamic acid 100 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Tranexamic Acid After Vaginal Delivery with Episiotomy a RCT Placebo Control Trail
In Brief
A Phase 4 clinical trial evaluating Tranexamic acid and Placebo for Episiotomy Wound and 3 related conditions. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The objective of this study is to assess the effect of TA treatment on decline in Hb levels following vaginal delivery with an episiotomy, compared to a control group not receiving TA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisiotomy Wound, Anemia, Early Postpartum Hemorrhage, Hemoglobin
CountriesIsrael
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartJul 2022
Primary CompletionAug 2023
Study CompletionSep 2024
TodayJul 2026
First PostedJul 7, 2022
Enrollment StartJul 25, 2022
Primary CompletionAug 22, 2023
Study CompletionSep 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.0 years ago
Interventions
Tranexamic aciddrug
1 gram of tranexamic acid in 100 ml of 0.9% normal saline
Placebodrug
100 ml of 0.9% normal saline